Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Daliresp Sales Pitch Draws FDA Letter After Forest Fails To Heed Advisory Comments

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency says the violation occurred despite FDA’s criticism of proposed promotional material for the respiratory drug and an ongoing corporate integrity agreement intended to block improper promotion.

You may also be interested in...

Carl Icahn’s Partial Victory In Battle For Forest: One Board Seat

Primary care-focused pharma reports that preliminary voting results show former OSI executive Pierre Legault was elected to the Forest board, replacing long-time member and outgoing compensation committee Chairman Dan Goldwasser.

Forest’s Respiratory Pipeline: Can It Open The Revenue Airway?

At a June 20 analyst meeting, Forest Labs discussed the potential for its respiratory pipeline, including the recently launched Daliresp and the yet-to-be approved aclidinium, which has a July PDUFA date.

Could Forest's DDMAC Letter For Off-Label Promotion Doom CEO Solomon?

A physician complained to FDA's "Bad Ad" program about a Forest Laboratories sales representative's off-label claims for the fibromyalgia drug Savella.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts